- ≥99% HPLC purity
- Lot-matched certificate of analysis
- Ships next business day, tracked
BPC-157 Troches (Sublingual)
Sublingual troche format of the gastric pentadecapeptide, 500 mcg per unit
- FormSublingual troche in a slowly dissolving compounding base
- Research areasGastrointestinal mucosal integrity, barrier function, transmucosal peptide delivery, formulation stability
Supplied for laboratory research use only. Not for human or veterinary use, and not intended to diagnose, treat, cure or prevent any disease.
Overview
These troches present BPC-157 in a slowly dissolving sublingual base rather than as a lyophilized powder for reconstitution. Each unit carries 500 micrograms of the pentadecapeptide and the pack holds thirty. The peptide itself is identical to the material in our vials and capsules: the 15-residue sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, corresponding to a partial fragment of body protection compound from human gastric juice, made by solid-phase synthesis and purified to at least 99% by HPLC.
BPC-157 is an unusual candidate for transmucosal work because it is unusually stable for a peptide of its length. Its parent protein is native to the stomach, and published stability work reports that the fragment tolerates acidic aqueous conditions that would rapidly degrade most peptides. That property is precisely why oral, intragastric and now transmucosal routes appear in the literature instead of parenteral administration alone.
Specifications
Supply & purity
- Form
- Sublingual troche in a slowly dissolving compounding base
Additional detail
- Peptide content
- 500 mcg BPC-157 per troche
- Available size
- 30 troches per pack
- Active component
- BPC-157, synthetic gastric pentadecapeptide
- Amino acid sequence (active)
- Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- CAS number (active)
- 137525-51-0
- Molecular formula (active)
- C62H98N16O22
- Molecular weight (active)
- 1419.55 g/mol
- Peptide purity
- ≥99% by HPLC before compounding; lot-matched COA available
- Delivery route studied
- Sublingual and buccal mucosal absorption
- Research areas
- Gastrointestinal mucosal integrity, barrier function, transmucosal peptide delivery, formulation stability
- Preparation required
- None — fixed unit content, no reconstitution or dilution step
- Storage
- Cool, dry and dark in the closed pack; refrigeration extends shelf stability
Questions about BPC-157 Troches (Sublingual)
How do the troches differ from BPC-157 capsules?
Both are fixed 500 mcg units of the same peptide, but release site differs. A capsule delivers its contents into the gastrointestinal tract; a troche dissolves against oral mucosa, so a fraction of the peptide can cross that epithelium directly and bypass first-pass hepatic metabolism.
Is the peptide the same as the vialed powder?
Yes. The same solid-phase synthesised, HPLC-purified BPC-157 is used for our vials, capsules and troches. Only the presentation differs, which is what makes matched format-comparison experiments possible without introducing a second material variable.
How much peptide crosses the mucosa?
That is the research question rather than a published constant. Peptides in this molecular-weight range generally show modest transmucosal permeation, and measuring the crossing fraction under defined formulation conditions is exactly what troche-format studies are designed to establish.
What purity documentation is available?
The peptide used in manufacture is released at ≥99% purity by reversed-phase HPLC and a lot-matched certificate of analysis is available. Keeping that COA with your record maintains traceability between the compounded units and the peptide lot they contain.
Why is storage temperature emphasised?
Troche bases soften with heat and absorb atmospheric moisture, which deforms the units and accelerates peptide degradation. Cool, dry, dark storage in a closed pack keeps both the physical form and the peptide content stable across the intended working window.
Related
